Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session

Mahmoud Al Rifai, Xiaoming Jia, Mouaz H. Al-Mallah, Michael D. Miedema, Seth Martin, Salim S. Virani

Research output: Contribution to journalReview article

Abstract

Purpose of Review: At the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented. Recent Findings: The CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein cholesterol. Post hoc analyses from the REDUCE-IT trial evaluated the efficacy of icosapent ethyl for lowering risk of total (first time and recurrent) CVD events. A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD risk. The CREOLE trial compared three different combination antihypertensive therapies for blood pressure lowering among black individuals in sub-Saharan Africa. The INFINITY trial examined the effect of intensive blood pressure control on progression of brain white matter changes and various components of mobility and cognitive function. Lastly, post hoc analyses from DECLARE-TIMI 58 evaluated the efficacy of dapagliflozin among patients with type 2 diabetes mellitus and heart failure or peripheral artery disease. Summary: These trials hold future promise for novel agents aimed at reducing CVD burden among high-risk patients who continue to experience CVD events despite treatment with currently available guideline-directed therapy.

Original languageEnglish (US)
Article number31
JournalCurrent atherosclerosis reports
Volume21
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Cardiovascular Diseases
Randomized Controlled Trials
Blood Pressure
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoprotein(a)
Africa South of the Sahara
Peripheral Arterial Disease
LDL Cholesterol
Type 2 Diabetes Mellitus
Cognition
Antihypertensive Agents
Therapeutics
Heart Failure
Guidelines
Safety
Acids
Brain

Keywords

  • Atherosclerotic cardiovascular disease
  • Cardiovascular disease
  • Heart failure
  • Prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. / Al Rifai, Mahmoud; Jia, Xiaoming; Al-Mallah, Mouaz H.; Miedema, Michael D.; Martin, Seth; Virani, Salim S.

In: Current atherosclerosis reports, Vol. 21, No. 8, 31, 01.08.2019.

Research output: Contribution to journalReview article

@article{207a255fb72e4f0eb8030926a2f20a74,
title = "Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session",
abstract = "Purpose of Review: At the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented. Recent Findings: The CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein cholesterol. Post hoc analyses from the REDUCE-IT trial evaluated the efficacy of icosapent ethyl for lowering risk of total (first time and recurrent) CVD events. A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD risk. The CREOLE trial compared three different combination antihypertensive therapies for blood pressure lowering among black individuals in sub-Saharan Africa. The INFINITY trial examined the effect of intensive blood pressure control on progression of brain white matter changes and various components of mobility and cognitive function. Lastly, post hoc analyses from DECLARE-TIMI 58 evaluated the efficacy of dapagliflozin among patients with type 2 diabetes mellitus and heart failure or peripheral artery disease. Summary: These trials hold future promise for novel agents aimed at reducing CVD burden among high-risk patients who continue to experience CVD events despite treatment with currently available guideline-directed therapy.",
keywords = "Atherosclerotic cardiovascular disease, Cardiovascular disease, Heart failure, Prevention",
author = "{Al Rifai}, Mahmoud and Xiaoming Jia and Al-Mallah, {Mouaz H.} and Miedema, {Michael D.} and Seth Martin and Virani, {Salim S.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1007/s11883-019-0789-3",
language = "English (US)",
volume = "21",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "8",

}

TY - JOUR

T1 - Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session

AU - Al Rifai, Mahmoud

AU - Jia, Xiaoming

AU - Al-Mallah, Mouaz H.

AU - Miedema, Michael D.

AU - Martin, Seth

AU - Virani, Salim S.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Purpose of Review: At the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented. Recent Findings: The CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein cholesterol. Post hoc analyses from the REDUCE-IT trial evaluated the efficacy of icosapent ethyl for lowering risk of total (first time and recurrent) CVD events. A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD risk. The CREOLE trial compared three different combination antihypertensive therapies for blood pressure lowering among black individuals in sub-Saharan Africa. The INFINITY trial examined the effect of intensive blood pressure control on progression of brain white matter changes and various components of mobility and cognitive function. Lastly, post hoc analyses from DECLARE-TIMI 58 evaluated the efficacy of dapagliflozin among patients with type 2 diabetes mellitus and heart failure or peripheral artery disease. Summary: These trials hold future promise for novel agents aimed at reducing CVD burden among high-risk patients who continue to experience CVD events despite treatment with currently available guideline-directed therapy.

AB - Purpose of Review: At the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented. Recent Findings: The CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein cholesterol. Post hoc analyses from the REDUCE-IT trial evaluated the efficacy of icosapent ethyl for lowering risk of total (first time and recurrent) CVD events. A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD risk. The CREOLE trial compared three different combination antihypertensive therapies for blood pressure lowering among black individuals in sub-Saharan Africa. The INFINITY trial examined the effect of intensive blood pressure control on progression of brain white matter changes and various components of mobility and cognitive function. Lastly, post hoc analyses from DECLARE-TIMI 58 evaluated the efficacy of dapagliflozin among patients with type 2 diabetes mellitus and heart failure or peripheral artery disease. Summary: These trials hold future promise for novel agents aimed at reducing CVD burden among high-risk patients who continue to experience CVD events despite treatment with currently available guideline-directed therapy.

KW - Atherosclerotic cardiovascular disease

KW - Cardiovascular disease

KW - Heart failure

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=85066240404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066240404&partnerID=8YFLogxK

U2 - 10.1007/s11883-019-0789-3

DO - 10.1007/s11883-019-0789-3

M3 - Review article

VL - 21

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 8

M1 - 31

ER -